TICKERNERD
Menu
SABSHealthcare · Biotechnology

SABS Stock Forecast: SAB Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 11 Sept 2026
$3.41
−0.29% on the day

The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. hold a median 12-month price target of $12 — +251.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 37 of 100 as at 12 Sept 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$310.3M
Ticker Nerd rank
37 / 100
Median analyst target
$12
Analysts covering
11
Revenue$0.0
Operating income−$23.4M
Net income−$22.5M
Free cash flow−$11.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−8.3%
1M
−9.3%
YTD
−8.8%
1Y
+60.8%
From 52W high
−25.7%
From 52W low
+74.9%
$1.95
$4.59
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SABS stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores SAB Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 12 Sept 2026
37 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Volatility
77
Momentum
75
Quality
69
Size
61
Growth
50
Revisions
33
Issuance
32
Value
31
Accruals
13

Volatility (77): The share price has been relatively steady.

Accruals (13): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SABS stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SABS, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Oct 25Jan 26Apr 26Jul 26SABSHigh $16Median $12Low $6

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says11 analysts
11 Buy0 Hold0 Sell
Low $6Median $12High $16

The green dot is the last close — the median target sits +251.9% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
24 June 2026BarclaysInitiatesOverweight$13
17 June 2026Chardan CapitalMaintainsBuy$14 → $16
15 June 2026HC Wainwright & Co.ReiteratesBuy—
15 June 2026Leerink PartnersMaintainsOutperform—
22 May 2026CitigroupInitiatesBuy—
20 May 2026JefferiesInitiatesBuy—
12 May 2026HC Wainwright & Co.MaintainsBuy—
11 May 2026Rodman & RenshawReiteratesBuy—
2 Apr 2026Rodman & RenshawInitiatesBuy—
11 Mar 2026Chardan CapitalMaintainsBuy—
10 Mar 2026HC Wainwright & Co.MaintainsBuy—
7 Jan 2026UBSInitiatesBuy—
19 Dec 2025GuggenheimInitiatesBuy—
18 Dec 2025Chardan CapitalMaintainsBuy—
17 Nov 2025Chardan CapitalMaintainsBuy—
19 Sept 2025Chardan CapitalMaintainsBuy—
17 Sept 2025Leerink PartnersInitiatesOutperform—
8 Aug 2025Chardan CapitalMaintainsBuy—
22 July 2025HC Wainwright & Co.MaintainsBuy—
15 May 2025Chardan CapitalMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SABS appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SABS vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 11 Sept 2026, SAB Biotherapeutics, Inc. returned +60.8% against +17.5% for the S&P 500, dividends included.

SABS vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200Oct 25Jan 26Apr 26Jul 26SABSS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SABS analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

SAB Biotherapeutics, Inc. (SABS) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
14.2×

Cheaper than 48% of US stocks

Price / sales
—
Price / book
1.3×

Cheaper than 62% of US stocks

EV / EBITDA
−3.1×

Cheaper than 75% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−11.3%

Higher than 35% of US stocks

Return on assets
−33.5%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

SAB Biotherapeutics, Inc. (SABS) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • SAB Biotherapeutics, Inc. has a market value of $310.3M and an enterprise value of $212.8M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.8M.

  • Free cash flow in the twelve months to 30 June 2026: −$57.4M.

  • Shares outstanding: 83.5M.

  • Trailing P/E: 14.2×; forward P/E: −3.6× — the forward figure prices analyst consensus estimates, not reported earnings.

  • SAB Biotherapeutics, Inc. employs 86 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 13 Sept 2026

Data provided by Twelve Data

Peers

SABS vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SABSSAB Biotherapeutics, Inc.$310.3M
37
AGENAgenus, Inc.$310.6M
91
ABEOAbeona Therapeutics, Inc.$308.9M
41
IFRXInflaRx NV$307.8M
9
UPBUpstream Bio, Inc.$313.8M
27
VNDAVanda Pharmaceuticals, Inc.$300.9M
44
IKTInhibikase Therapeutics, Inc.$326.5M
33

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own SAB Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SABS news & analysis

SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript

Seeking Alpha · 10 Sept 2026neutral

SAB Biotherapeutics, Inc. (SABS) presented at Citigroup's Biopharma Back to School Summit 2026, and the transcript of that presentation was published on Seeking Alpha. The presentation features SAB's participation in the summit event.

Why it matters — A SABS watcher would care because the presentation at a major industry summit provides insight into the company's positioning and visibility with institutional investors.

SAB BIO to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

SAB Biotherapeutics announced that members of its management team will participate in upcoming investor conferences in September. The company is a clinical-stage biopharmaceutical firm developing a fully human anti-thymocyte immunoglobulin for type 1 diabetes and other autoimmune diseases.

Why it matters — SABS watchers would be interested to know that management will be presenting to investors at upcoming conferences, which could raise awareness of the company's pipeline.

SAB Biotherapeutics Q2 Earnings Call Highlights

MarketBeat · 7 Aug 2026neutral

During its Q2 earnings call, SAB Biotherapeutics said its registrational Phase IIb SAFEGUARD trial of SAB-142 in newly diagnosed Stage 3 Type 1 diabetes remains on track to complete enrollment in the fourth quarter of 2026, with top-line data expected in the second half of 2027.

Why it matters — The update reaffirms the expected clinical development timeline for SAB-142, the company's lead candidate, which is central to SABS watchers following its progress.

SAB BIO Reports Q2 2026 Financial Results and Provides Business Highlights

GlobeNewsWire · 6 Aug 2026positive

SAB Biotherapeutics reported its Q2 2026 financial results and provided business updates. Over 60 clinical sites have been activated in the registrational SAFEGUARD study of SAB-142 in Stage 3 new onset type 1 diabetes, with enrollment on track for completion in Q4 2026 and topline data expected in 2H 2027. The company also noted a grant to the PRISE-hATG study and an operational runway through 2028.

Why it matters — The update confirms SAB-142's SAFEGUARD trial is progressing on schedule with expanded site activation and funding that supports operations through 2028, providing clarity on key clinical milestones ahead.

FAQ

Frequently asked questions about SABS stock

What is the SABS stock price forecast for 2026-2027?

The 11 Wall Street analysts covering SAB Biotherapeutics, Inc. have a median 12-month price target of $12, with estimates ranging from $6 to $16. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SABS stock a buy right now?

Of the 11 analysts covering SAB Biotherapeutics, Inc., 11 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks SAB Biotherapeutics, Inc. 37 out of 100 across roughly 4,600 US stocks as at 12 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SABS?

As at 12 Sept 2026, SAB Biotherapeutics, Inc. ranks 37 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (77 of 100).

Will SABS stock go up?

No one can know that. What the data says: the median 12-month target from 11 analysts implies +251.9% from the last close, and Ticker Nerd's factor model ranks SAB Biotherapeutics, Inc. 37 out of 100 as at 12 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SABS stock forecast for 2030?

No analyst covering SAB Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SABS are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6 to $16 over the next 12 months.

How has SABS stock performed over the past year?

SAB Biotherapeutics, Inc. returned +60.8% over the 12 months to 11 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does SAB Biotherapeutics, Inc. do?

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases.

What is the latest news on SABS?

The most recent item we track (Seeking Alpha, 10 Sept 2026): "SAB Biotherapeutics, Inc. (SABS) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript". SAB Biotherapeutics, Inc. (SABS) presented at Citigroup's Biopharma Back to School Summit 2026, and the transcript of that presentation was published on Seeking Alpha. The presentation features SAB's participation in the summit event.

Company

About SAB Biotherapeutics, Inc.

SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing fully human polyclonal immunotherapies for immune and autoimmune disorders, as well as infectious diseases. The company’s platform is designed to produce high-potency antibody therapies without relying on human donors or convalescent plasma, using a proprietary approach to generate targeted immunoglobulins. Its current pipeline is centered on SAB-142, a lead product candidate being developed for autoimmune type 1 diabetes. SAB Biotherapeutics Inc. also applies its DiversitAb platform to create multi-target antibody medicines intended for difficult-to-treat conditions across immunology and infectious disease. Based in the United States, the company operates in the biotechnology sector, where it contributes to the development of next-generation antibody-based treatments for patients with significant unmet medical needs.

CEO Mr. Samuel J. Reich · 86 employees · United States · https://www.sab.bio